Abbott to Become No.1 Pharmaceutical Company in India

By: Pharma News | Views: 5902 | Date: 08-Jul-2013

Abbott (NYSE: ABT) announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and a


Abbott to Become No. 1 Pharmaceutical Company in India

Abbott (NYSE: ABT) announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio.

"This strategic action will advance Abbott into the leading market position in India, one of the world's most attractive and rapidly growing markets," said Miles D. White, chairman and chief executive officer, Abbott. "Our strong position in branded generics and growing presence in emerging markets is part of our ongoing diversified pharmaceutical strategy, complementing our market-leading proprietary pharmaceutical offerings and pipeline in developed markets."

 

"Emerging markets represent one of the greatest opportunities in health care - not only in pharmaceuticals - but across all of our business segments. Today, emerging markets represent more than 20 percent of Abbott's total business," said Mr. White.

"With this deal, the combined Healthcare Solutions and Abbott businesses will become the clear market leader in India, with a market share of approximately 7 percent," said Ajay Piramal, chairman, Piramal Group. "This was our collective vision and I am glad that those who are part of Piramal's Healthcare Solutions business will realize this dream."

 

The Indian Pharmaceutical Market
India is one of the world's fastest-growing pharmaceutical markets, due in large part to branded generics. The market will generate nearly $8 billion in pharmaceutical annual sales this year, a number that is expected to more than double by 2015. Abbott estimates the growth of its Indian pharmaceutical business with Piramal to approach 20 percent annually, with expected sales of more than $2.5 billion by 2020.

 

Branded generics have significant brand equity in many international markets, providing durable, sustainable franchises for future growth. Piramal markets the products in its Healthcare Solutions business in India only and does not market traditional generic products. Today, branded generics account for 25 percent of the global pharmaceutical market, have the majority of market share in the largest emerging markets, and are expected to outpace growth of patented and generic products.

 

The Mumbai-based Piramal Healthcare Solutions business has a comprehensive portfolio of branded generics with annual sales expected to exceed $500 million next year in India, and market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience. This business grew 23 percent in 2010 (fiscal year ended March 31, 2010), faster than the market in India. Piramal has a strong commercial presence, including the largest sales force in India with a unique model that includes dedicated sales personnel in rural areas inhabited by 70 percent of the population. The combined Abbott and Piramal sales forces will be the industry's largest in India.

 

Piramal's Healthcare Solutions business will become part of Abbott's newly created, stand-alone Established Products Division. Piramal's Healthcare Solutions business employs more than 5,000 people in India. Abbott, which is celebrating its 100th year in India, has more than 2,500 employees across all of its businesses there.

 

Abbott's Established Products Strategy
Throughout the past decade, Abbott has built a leading portfolio of branded generics, through its own products as well as those acquired with the 2001 acquisition of Knoll's pharmaceutical business. In 2007, the company established a separate business unit within its international pharmaceutical division dedicated to established products.

 

Additionally, a new geographic region focused on Russia, India and China was created, which resulted in the doubling of Abbott's growth rate in those countries.

 

Most recently, the company acquired Solvay Pharmaceuticals, obtaining a diverse branded generics portfolio and providing significant critical mass in key emerging markets.

 

As a result of these combined actions, Abbott is now among the leading multinational health care companies in numerous emerging markets. Approximately 20 percent of Abbott's pharmaceutical sales today are in emerging markets.

 

"We have assembled a market-leading branded generics portfolio tailored to the unique needs of emerging markets, strongly positioning Abbott to meet the current and future geographic and market dynamics in pharmaceuticals," said Olivier Bohuon, executive vice president, global pharmaceuticals, Abbott. "Piramal has built a reputation for high-quality, well-known and trusted pharmaceutical brands. We look forward to welcoming the accomplished staff of Piramal's Healthcare Solutions business to Abbott."

 

Pharmaceutical sales in emerging markets are expected to grow at three times the rate of developed markets and account for 70 percent of pharmaceutical growth over the next several years. This explosive growth is occurring as demographics, rising incomes, modernization of health systems and an increase in the treatment of chronic disease create greater demand for medicines.

 

Financial Highlights
Under terms of the agreement, Abbott will purchase the assets of Piramal's Healthcare Solutions business for a $2.12 billion up-front payment with payments of $400 million annually for the next four years, beginning in 2011. The transaction will not impact Abbott's ongoing earnings per share guidance in 2010. Abbott plans to fund the transaction with cash on the balance sheet.

 

This transaction is subject to shareholder approval of Piramal Healthcare Limited and other customary closing conditions, and is expected to close in the second half of 2010. This transaction is being conducted by a wholly-owned subsidiary of Abbott, resulting in full ownership of the assets of Piramal's Healthcare Solutions business (Domestic Formulations).

 

About the Piramal Group
The Piramal Group, led by Ajay G. Piramal is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical and value driven practices. The Group's turnover exceeded US $1 billion in FY2010.

 

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

Previous Page Next Page

People Searching On This Page:
  • abbott pharma poisitonnement
  • top 1pharmaceutical companies of Indiaal
  • no1pharmaceutical company in the world
  • no 1pharmaceutical marketing company
  • abbott india
  • abbott india entities piramal domestic formulations
  • pharmaceutical healthcare company logo
  • indain pharmaceutical company acqusition at international front
  • strategy of abbott for india
  • position of abbott according to international pharmaceutical
  • abots multinational companies in india abt pharmacy
  • no 1 possion pharma industry india
  • TEXT

Related Pages


61st International Pharmaceutical Students (IPA) -2015

61st International Pharmaceutical Students (IPA) -2015

News | Exhibitions & Conferences
Date:
18-Mar-2015  Views: 2062

Indian Pharmaceutical Association (IPA) is the premier professional association of pharmaceutical professionals in India. IPA is affiliated with inter ...
Biocon net profit falls 13% to Rs 91 cr; to offload 10-15% in Syngene

Biocon net profit falls 13% to Rs 91 cr; to offload 10-15% in Syngene

News | Pharma Companies
Date:
11-Feb-2015  Views: 1352

Biotech firm Biocon on Thursday reported a 13 per cent fall in net profit for October-December quarter at Rs 91 crore and said it will sell 10-15 per ...
1st Indian Cancer Congress - 2013

1st Indian Cancer Congress - 2013

News | Exhibitions & Conferences
Date:
24-Aug-2013  Views: 4831

Dear Friends,1st Indian Cancer Congress -2013 ConferenceA specialist is one who dedicates self to one area of work; someone who continuously strives t ...
Influenza Virus Vaccine for the 2011 - 2012 Season

Influenza Virus Vaccine for the 2011 - 2012 Season

Articles | Pharmaceutical Drugs
Date:
10-Oct-2011  Views: 3801

Cumulative 2011/2012 Season Lot Release Status ...
Top 10 Pharmaceutical Companies in India

Top 10 Pharmaceutical Companies in India

Articles | Pharma Companies
Date:
21-Jul-2011  Views: 131179

In the list of top pharmaceutical companies in India it is not the Indian companies but also the MNCs that are becoming the part of the race. Indian p ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

63  + 2 =     
Comments
Sophie Turner  |  10-Jan-2017 18:27:26 IST
Exhibitor opportunity at Natural Products 2017

Dear Manager,

Greetings from Natural Products 2017!

Conference Series LLC cordially invites you to the “2nd International Conference and Exhibition on Marine Drugs and Natural Products going to be held from June 15-17, 2017 in London, United Kingdom.

The theme of the conference is “Nature as a Medicine”.

The conference provides an exceptional opportunity to promote your organization and would be an excellent chance to meet colleagues, to exchange knowledge and experience, and to extend your list of contacts.
This event will provide a broad ranging platform for informative and interactive discussions with contributions by recognized experts from:
• Industry
• Associations
• Academia

Have a glance on various opportunities at Natural Products 2016:

Sponsorships/Exhibitions Prices
Elite sponsor USD 7500
Gold sponsor USD 5000
Silver sponsor USD 3500
Exhibitions USD 1500


Natural Products 2017 is offering Exhibitor opportunity at the venue who intends to showcase their new and emerging technologies.

Exhibitor Benefits:
• One complimentary congress registration
• One complimentary speaker opportunity
• An opportunity to sponsor 1 Poster Presentation Award
• One exhibit booth (Size-3X3 sqm)
• Logo recognition on congress website sponsorship page
• Verbal recognition during Opening and Closing Ceremony
• One page add in conference souvenir
• One insert provided by the exhibitor in the congress delegate bags

The organizing committee would like to invite you and your organization to be a part of conference as an Exhibitor.
For more information about sponsor/Exhibitor opportunity, Please visit http://naturalproducts.pharmaceuticalconferences.com/sponsors.php

For more information on how your organization could benefit from this event and to discuss the full range of lead generating, networking and branding opportunities that exist, feel free to contact the undersigned.

We look forward to have your valuable association with our conference.

Awaiting your response

Thanks & Regards
Sophie Turner
Natural Products 2017
Conference Series
Direct: (702) 508-5200
Customer Service: +1 (800) 216 6499
Email- naturalproducts@conferenceseries.net, naturalproducts@pharmaceuticalconferences.org

http://www.conferenceseries.com/
People Searched About:
Abbott Pharma Poisitonnement   |   Top 1Pharmaceutical Companies Of Indiaal   |   No1pharmaceutical Company In The World   |   No 1Pharmaceutical Marketing Company   |   Abbott India   |   Abbott India Entities Piramal Domestic Formulations   |   Pharmaceutical Healthcare Company Logo   |   Indain Pharmaceutical Company Acqusition At International Front   |   TEXT   |  
Google : 226 times | Yahoo : 15 times | Bing : 78 times |